Overview
The regulatory landscape for AI in GxP environments is rapidly evolving as regulatory bodies develop frameworks to ensure the safe and effective use of artificial intelligence in pharmaceutical development and manufacturing. In January 2026, the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) jointly published ten guiding principles for the use of AI in drug development . This significant step toward harmonization signals a clear direction for AI governance in regulated environments. This guide explores the current regulatory landscape for AI in GxP and the training programs available to help organizations navigate these requirements.
https://www.gxptrainings.com/course-category/ai-in-gxp-trainings
EMA’s Approach to AI in GxP
The EMA has been actively developing its regulatory framework for AI in pharmaceutical manufacturing. The EMA’s reflection paper emphasizes that AI applications in manufacturing must comply with GMP and data integrity standards, while applications affecting clinical decisions or regulatory submissions require additional scrutiny proportional to their impact on patient safety and regulatory decision-making .
EU GMP Annex 11 Revision – The 2025 revision of Annex 11 expands from 5 pages to 19, with 17 sections, introducing much more specific, practical, and up-to-date requirements for computerized systems. This provides the foundation for AI validation in GMP environments.
Draft Annex 22 – For the first time, Draft Annex 22 provides a dedicated regulatory framework specifically for AI models in the GMP environment. This is a significant development that organizations must understand.
AI System Impact Assessment – The EMA emphasizes systematic evaluation of consequences on individuals, groups, and societies throughout the AI system lifecycle, following the ISO/IEC 42001 framework.
FDA’s Approach to AI in GxP
The FDA has been developing its approach to AI through multiple guidance documents and regulatory actions. The FDA defines Artificial Intelligence as “a machine-based system that can, for a given set of human-defined objectives, make predictions, recommendations, or decisions influencing real or virtual environments” .
FDA 510(k) Pathway – A systematic analysis of FDA-authorized AI/ML medical devices found that 76% of the over 950 devices authorized as of mid-2024 were in radiology, with 96.4% of these authorizations cleared through the 510(k) pathway .
Computer Software Assurance Guidance – The FDA has shifted from traditional CSV toward Computer Software Assurance (CSA), emphasizing risk-based approaches and critical thinking.
Data Integrity Requirements – The FDA maintains strict data integrity requirements under 21 CFR Part 11, which apply to AI systems.
Joint EMA-FDA Guiding Principles
In January 2026, the EMA and FDA jointly published ten guiding principles for AI in drug development . These principles include:
Adherence to Standards – AI systems are expected to comply with relevant legal, ethical, technical, scientific, and regulatory standards, including GxP .
End-to-End Traceability – Data provenance, processing, and analytical decisions must be traceable, verifiable, and aligned with GxP expectations .
Clarity of Purpose – AI systems should have a clearly defined role and scope within the discovery workflow, and their outputs should be understandable and relevant to the intended user .
Risk-Based Validation – Performance assessments should account for model behavior, human-AI interaction, and the context in which the system is used. Validation is treated as an ongoing responsibility rather than a one-time milestone .
Lifecycle Oversight – Regular monitoring and reassessment are expected as data, models, and use cases evolve.
The ISPE GAMP Guide: Artificial Intelligence
The ISPE GAMP Guide: Artificial Intelligence (published July 2025) bridges established GAMP concepts with the unique characteristics of AI systems in GxP environments. It provides practical guidance for validating AI systems based on risk and critical thinking.
Detailed Course Breakdown
Course 1: Validating AI in GxP – A Comprehensive Training
This comprehensive training program provides a deep and practical understanding of how to validate, govern, and maintain AI systems in GxP-regulated environments. It integrates the latest regulatory frameworks, including EU GMP Annex 11, the new Draft Annex 22, FDA’s Computer Software Assurance Guidance, 21 CFR Part 11, and the ISPE GAMP Guide: Artificial Intelligence.
Scope: The program addresses the critical question: “How do you validate something that can learn?” It covers AI system classification and risk tiering, data governance, performance acceptance criteria, test data management, ongoing monitoring, drift detection, and retraining governance.
Description of Modules: The curriculum covers 25 comprehensive sections across six parts:
- Part 1: Getting Your Bearings – AI concepts, regulatory spine, and why AI validation breaks traditional CSV
- Part 2: Classify and Govern – classification and risk tiering, AI governance operating model, and AI validation master plan
- Part 3: Build the Evidence – data governance for AI, performance acceptance criteria, test data and the three independences, and IQ/OQ/PQ redefined for AI
- Part 4: Keep It Valid Over Time – ongoing monitoring and drift response, explainability and confidence, change control and retraining, and AI risk management
- Part 5: Prove It and Scale It – inspection readiness, generative AI in non-critical GxP use, LLMs in regulated environments, and building the AI programme
- Part 6: Advanced Topics – AI and data integrity (ALCOA+), cybersecurity for AI systems, AI in combination products and SaMD, vendor management, and future trends
Target Audience:
- Validation Engineers and CSV Specialists
- Quality Assurance Professionals
- Data Scientists and AI/ML Engineers
- Regulatory Affairs Professionals
- IT and Cybersecurity Professionals
- Senior Management and AI Program Leaders
- Auditors and Inspectors
Pricing: $399.00 with group discounts available.
FAQ:
- What is the difference between FDA and EMA approaches to AI in GxP? The FDA takes a more permissive stance, allowing for adaptive and generative AI systems with appropriate governance, while the EMA’s draft Annex 22 takes a more conservative approach, restricting dynamic, probabilistic, and generative models from critical GMP applications.
- What is Draft Annex 22? Draft Annex 22 is a new EU GMP Annex that provides a dedicated regulatory framework specifically for AI models in the GMP environment.
- What are the joint EMA-FDA guiding principles? In January 2026, the EMA and FDA jointly published ten guiding principles for AI in drug development, including adherence to standards, end-to-end traceability, clarity of purpose, and risk-based validation .
- What is the ISPE GAMP Guide: Artificial Intelligence? The ISPE GAMP Guide: Artificial Intelligence bridges established GAMP concepts with the unique characteristics of AI systems in GxP environments.
- How does the FDA define AI? The FDA defines AI as “a machine-based system that can, for a given set of human-defined objectives, make predictions, recommendations, or decisions influencing real or virtual environments” .
Enroll Now: https://www.gxptrainings.com/courses/validating-ai-in-gxp-a-comprehensive-training/
Course 2: AI Management Systems (ISO/IEC 42001:2023)
This comprehensive training program encompasses the full spectrum of requirements for establishing, implementing, maintaining, and continually improving an Artificial Intelligence Management System (AIMS) as mandated by ISO/IEC 42001:2023 – the world’s first international standard for AI management systems.
Scope: The program covers organizational context, leadership and commitment, risk management, AI system impact assessment, resource management, AI system lifecycle controls, data governance, third-party relationships, performance evaluation, and continual improvement.
Description of Modules: The curriculum covers 10 comprehensive modules.
Target Audience:
- AI Providers, Producers, and Developers
- AI Customers and Partners
- Quality Assurance and Compliance Professionals
- IT and Data Science Teams
- Regulatory Affairs Personnel
- Competent Authorities and Policymakers
Pricing: $249.00 with group discounts available.
FAQ:
- What is ISO/IEC 42001:2023? ISO/IEC 42001:2023 is the world’s first international standard for Artificial Intelligence Management Systems.
- What is an AI System Impact Assessment? An AI System Impact Assessment is a systematic evaluation of the consequences of an AI system on individuals, groups, and societies.
- Who should take this training? Any organization wishing to implement an AIMS, regardless of size or nature.
- How does ISO/IEC 42001 support regulatory compliance? It provides a management system framework for AI that aligns with regulatory expectations.
- What is the time commitment for this training? Approximately 18-24 hours of training, including assessments.
Enroll Now: https://www.gxptrainings.com/courses/ai-management-systems-iso-iec-420012023/
Course 3: Designing AI Driven Workflows in Life Sciences
This self-directed training program is designed for the full range of life sciences roles, drawing on real world case studies, specific performance statistics, and proven frameworks.
Scope: The program covers AI applications across life sciences, including drug discovery, clinical trials, manufacturing, quality assurance, supply chain, and regulatory affairs.
Description of Modules: The curriculum covers six comprehensive modules.
Target Audience:
- Senior management
- Quality assurance professionals
- GxP operations leads
- Clinical operations managers
- Regulatory affairs specialists
- Manufacturing supervisors
- Supply chain planners
- R&D scientists
- Medical affairs teams
Pricing: $349.00 with group discounts available.
FAQ:
- How does this course address regulatory requirements? It covers validation protocols and regulatory submission requirements for AI-driven workflows.
- What is the typical ROI for AI in life sciences? AI deployments have shown significant returns across various applications.
- What are the common pitfalls in AI workflow design? Common pitfalls include poor data quality and lack of clear business objectives.
- Do I need programming skills to take this course? No.
- What certification do I receive? Learners will receive a dated, traceable certificate of completion.
Enroll Now: https://www.gxptrainings.com/courses/designing-ai-driven-workflows-in-life-sciences/
Course 4: AI for Life Sciences Professionals
This training program is designed to equip life sciences professionals with the practical knowledge needed to lead, manage, or contribute to AI initiatives. No prior programming or advanced mathematics is assumed.
Scope: This program covers foundational concepts including neural networks, machine learning types, deep learning, and Explainable AI.
Description of Modules: The curriculum covers:
- Artificial Intelligence defined in practical terms
- Distinguishing AI from traditional rule-based programming
- Neural networks, machine learning, and deep learning functions
- Key technological drivers transforming life sciences
- Real-world AI applications
- Strategic frameworks
- Phased AI adoption journey
- Ethical, regulatory, and validation challenges
Target Audience:
- Research scientists
- Clinical research associates
- Medical affairs professionals
- Laboratory managers
- Bioinformatics scientists
- Regulatory affairs professionals
- Healthcare providers
Pricing: $299.00 with group discounts available.
FAQ:
- Do I need programming skills to take this course? No.
- What is Explainable AI and why is it important? Explainable AI makes AI model decisions understandable to humans, which is critical for regulatory review.
- What is the 3-Horizon Model? The 3-Horizon Model is a strategic framework for assessing AI adoption.
- What is the AI Maturity Map? The AI Maturity Map is a framework for evaluating organizational readiness for AI adoption.
- How does this course support regulatory knowledge? It covers ethical, regulatory, and validation challenges.
Enroll Now: https://www.gxptrainings.com/courses/ai-for-life-sciences-professionals/
Course 5: Navigating Generative AI in Academic Research
This training program is designed to help researchers, students, and academic professionals navigate the opportunities and challenges of Generative AI in academic research.
Scope: This training covers the intersection of large language models and academic work.
Description of Modules: The curriculum covers:
- Generative AI usage growth in scientific literature
- Benefits of GenAI for researchers
- Specific risks including threats to academic integrity
- Established ethical frameworks
- Publisher policies
- Detection of AI-generated text
- Disclosure statement requirements
- Impact on education
Target Audience:
- Graduate students
- Early-career and established researchers
- Research integrity officers
- University educators
Pricing: $249.00 with group discounts available.
FAQ:
- Can AI be listed as an author? No.
- How does Generative AI impact research integrity? Generative AI can enable undisclosed AI-generated content.
- What is the Who, What, Where framework? This framework helps structure disclosure statements.
- How can researchers use Generative AI ethically? Ethical use requires transparency and following publisher policies.
- What are the limitations of AI-generated text detection? Detection tools may produce false positives or negatives.
Enroll Now: https://www.gxptrainings.com/courses/navigating-generative-ai-in-academic-research/
Get Your Team Offer
For organizations looking to enroll multiple participants, we offer specialized team packages and volume discounts. Please reach out to our partnership team to discuss your specific needs and scores.
Contact Us: https://www.gxptrainings.com/contact-us/
Author
